COVID-19. U07.1 - COVID-19
Conditions
Interventions
Intervention 1: Intervention group: hydroxychloroquine, 400 mg BD on the first day and 200 mg hydroxychloroquine BD daily on the second to seventh day and concurrent, Azithromycin at a dose of 500 mg
Sponsors
Quality Improvement of Intensive Care Research Center- Shahid Beheshti University
Eligibility
Sex/Gender
All
Age
16 Years to 100 Years
Inclusion criteria
Inclusion criteria: Diagnosis of COVID-19 based on either ground glass appearance in chest CT scan or positive RT-PCR test for COVID-19 Requiring hospitalization on the basis of level of consciousness,blood pressure, kidney and liver failure Patient's age between 16 and 100 years Signed informed consent form
Exclusion criteria
Exclusion criteria: Chronic liver and kidney failure HIV patients pregnancy and breast feeding QT interval more than 500 milliseconds
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Length of stay in the intensive care unit. Timepoint: Once (when discharged from intensive care unit). Method of measurement: Hospital records.;In-hopital mortality. Timepoint: once. Method of measurement: Medical records. | — |
Secondary
| Measure | Time frame |
|---|---|
| Length of stay in hospital. Timepoint: Once at discharge. Method of measurement: Patient medical records.;Radiological Treatment Response (CT scan) , more than 50% reduction in the affected area. Timepoint: CT scan will be done twice (once at the time of admission and the second time 10 days after discharge). Assessment will be done comparing the second CT with the first one. Method of measurement: Patient CT scan.;Laboratory Treatment Response; return of blood cell count and CRP values to normal. Timepoint: Daily. Method of measurement: Laboratory kits.;Fever. Timepoint: Daily. Method of measurement: Patient medical records.;Dyspnea. Timepoint: Daily. Method of measurement: Patient medical records.;Oxygen saturation without supplemental oxygen. Measurement will be done after discontinuation of oxygen therapy for 5 minutes. Timepoint: 4 times a day while in the wards. Method of measurement: Observation.;Adverse drug reactions. Timepoint: Daily. Method of measurement: Adverse Drug Reaction forms. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mohammad Fathi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed